FSNUY News and Press, Fresenius SE & Co KGaA ADR From 07/25/23

2023-07-25 06:22:00 ET Summary Denmark's Novo Nordisk is 100 years old this year, with fundamentals as strong as ever facing a population with record rates of obesity and diabetes. I almost wish NVO stock would decline by 50% due to a collapse in the demand for insulin, but that s...

2023-07-18 09:15:46 ET Summary The broad S&P500 edged up 1.2% in June, while the Dow Jones rose slightly by 0.8% during the month. Investment activity in June picked up significantly from May, with net investments totaling around $2,200, primarily targeted towards the financia...

2023-07-09 05:24:42 ET Summary Fresenius, a German healthcare company, is highlighted as a promising investment due to its global presence, market leadership, and potential for significant growth in the coming years. Despite underperforming in recent years, the company's new manag...

2023-07-05 12:57:34 ET South Korea's Celltrion ( OTC:CONIF ) has launched a high-concentration, citrate-free formulated biosimilar of AbbVie's ( NYSE: ABBV ) Humira in the US. The biosimilar, which is called Yuflyma, was approved by the FDA in May. Yuflyma's list price is $6...

2023-05-23 09:45:00 ET Summary Markets are racing higher as the earnings season turned out much better than expected. Sector rotation into tech stocks has led to a surge in big-tech with Nvidia clearly leading the pack. My dividend income in April amounted to a record $755. Th...

2023-04-23 07:22:20 ET Summary Fresenius reported solid results for fiscal 2022, but keeps missing its own growth target - at least for the bottom line. The company is also losing its status as dividend aristocrat and is keeping the dividend only stable after a streak of 29 consec...

2023-04-17 17:44:40 ET Summary This month I had 5 transactions. New forward dividends are approximately $1,121. Next month I will look at Morgan Stanley, Prudential Financial, CVS Health, and Brookfield Asset Management. March was a bad month for my portfolio, as it ...

2023-04-12 10:00:00 ET Summary Inflation and (expected) actions by the Federal Reserve continue to dominate market movements even though the turmoil in the financial sector shortly took center stage. Markets have started the new year with very solid gains following expectations ab...

2023-03-21 11:54:39 ET Summary What to "BUY" in this time of absolute turmoil is something to be carefully considered. I try to focus on undervalued, qualitative opportunities. These exist in every sector. Fresenius has long been a position of mine. In this article, I seek to upda...

2023-03-09 03:28:50 ET Summary This month, I had 5 transactions. New forward dividends are approximately $1,250. Next month, I will look into Prosus, Armada Hoffler, Enbridge, and L3harris. For further details see: My Portfolio February Update: 4 Buys...